Abstract

Objectives

Burden of comorbidities are largely unknown in JIA. From 2000, national and international patient registries were established to monitor biologic treatment, disease activity and adverse events in patients with JIA. The aim of this analysis was to investigate in parallel, for the first time, three of the largest JIA registries in Europe/internationally—UK JIA Biologic Registers (BCRD/BSPAR-ETN), German biologic registers (BiKeR/JuMBO), multinational Pharmachild—to quantify the occurrence of selected comorbidities in patients with JIA.

Methods

Information on which data the registers collect were compared. Patient characteristics and levels of comorbidity were presented, focusing on four key conditions: uveitis, MAS, varicella, and history of tuberculosis. Incidence rates of these on methotrexate/biologic therapy were determined.

Results

8066 patients were registered into the three JIA registers with similar history of the four comorbidities across the studies; however, varicella vaccination coverage was higher in Germany (56%) vs UK/Pharmachild (16%/13%). At final follow-up, prevalence of varicella infection was lower in Germany (15%) vs UK/Pharmachild (37%/50%). Prevalence of TB (0.1–1.8%) and uveitis (15–19%) was similar across all registers. The proportion of systemic-JIA patients who ever had MAS was lower in Germany (6%) vs UK (15%) and Pharmachild (17%).

Conclusion

This analysis is the first and largest to investigate the occurrence of four important comorbidities in three JIA registries in Europe and the role of anti-rheumatic drugs. Combined, these three registries represent one of the biggest collection of cases of JIA worldwide and offer a unique setting for future JIA outcome studies.

中文翻译：

---

幼年特发性关节炎儿童和青少年的共病负担：对 3 个 JIA 登记处的协作分析

摘要

目标

幼年特发性关节炎的合并症负担在很大程度上是未知的。从 2000 年起，建立了国家和国际患者登记处，以监测幼年特发性关节炎患者的生物治疗、疾病活动和不良事件。本分析的目的是首次并行调查欧洲/国际上三个最大的 JIA 注册机构——英国 JIA 生物注册机构 (BCRD/BSPAR-ETN)、德国生物注册机构 (BiKeR/JuMBO)、跨国公司 Pharmachild ——量化幼年特发性关节炎患者特定合并症的发生率。

方法

比较了寄存器收集的数据的信息。介绍了患者特征和合并症水平，重点关注四个关键病症：葡萄膜炎、MAS、水痘和结核病史。确定了甲氨蝶呤/生物治疗中这些疾病的发生率。

结果

8066 名患者被登记到三个 JIA 登记册中，这些患者在研究中四种合并症的病史相似；然而，德国 (56%) 的水痘疫苗接种覆盖率高于英国/Pharmachild (16%/13%)。在最终随访时，德国的水痘感染患病率 (15%) 低于英国/Pharmachild (37%/50%)。所有登记中的结核病 (0.1–1.8%) 和葡萄膜炎 (15–19%) 患病率相似。德国 (6%) 的系统性幼年特发性关节炎患者中曾患 MAS 的比例低于英国 (15%) 和 Pharmachild (17%)。

结论

这项分析是首次也是规模最大的一项分析，旨在调查欧洲三个 JIA 登记处四种重要合并症的发生情况以及抗风湿药物的作用。这三个登记处加起来代表了全球最大的幼年特发性关节炎病例集合之一，并为未来的幼年特发性关节炎结果研究提供了独特的环境。